Core Viewpoint - Four pharmaceutical companies, including Tianjin Pharmaceutical Co., Ltd. (Tianjin Pharma), Zhejiang Xianju Pharmaceutical Co., Ltd. (Xianju Pharma), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (Lianhuan Pharma), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd., were fined a total of 362 million yuan for price-fixing of dexamethasone raw materials, with Tianjin Pharma being penalized for the fourth time for similar monopolistic behavior [1][2][4]. Group 1: Companies Involved - Tianjin Pharma, Xianju Pharma, Lianhuan Pharma, and Xi'an Guokang Ruijin Pharma were involved in a price-fixing scheme for dexamethasone, leading to a significant increase in prices from 8,000 yuan/kg to 13,000 yuan/kg between February 2022 and March 2024 [2][4]. - Tianjin Pharma has a history of monopolistic practices, having been penalized multiple times since 2021 for various violations of antitrust laws [4][5]. - Lianhuan Pharma's fine represents 72.53% of its net profit, significantly impacting its financial performance [6][8]. Group 2: Regulatory Actions - The Tianjin Municipal Market Supervision Administration imposed fines based on the companies' previous year's sales, totaling 355 million yuan, along with confiscation of illegal gains [2][7]. - The regulatory body emphasized the importance of maintaining fair competition in the pharmaceutical sector and indicated a commitment to stricter enforcement of antitrust laws [2][4]. - Lianhuan Pharma has submitted a hearing request to reduce its penalties, but the regulatory authority rejected its arguments, affirming the validity of the evidence against the company [7]. Group 3: Financial Impact - Lianhuan Pharma reported revenues of 2.174 billion yuan and 2.160 billion yuan for 2023 and 2024, respectively, with net profits declining by 4.5% and 37.66% [6][8]. - The fine imposed on Lianhuan Pharma will reduce its net profit for 2025 by approximately 61.04 million yuan [8]. - Tianjin Pharma's market influence is significant, with a strong presence in the domestic market for steroid hormone raw materials [5].

Core Viewpoint - The article discusses the significant administrative penalties imposed on Xianju Pharmaceutical for participating in a price-fixing agreement regarding the raw material Dexamethasone Sodium Phosphate, highlighting the implications for corporate governance and compliance standards in the pharmaceutical industry [2][3][4]. Group 1: Penalty Details - The State Administration for Market Regulation imposed a total fine of 362 million yuan on four companies involved in the price-fixing agreement, with Xianju Pharmaceutical facing the highest penalty of 195 million yuan, which includes the confiscation of illegal gains and an 8% fine based on 2023 sales [2][3]. - The price of Dexamethasone Sodium Phosphate increased from 8,000 yuan per kilogram to 13,800 yuan per kilogram, marking a 62.5% rise due to the collusion among the companies [3]. Group 2: Corporate Governance and Compliance - The price-fixing behavior reflects a significant gap in Xianju Pharmaceutical's internal governance and compliance measures, contradicting their stated commitment to fair competition and ethical business practices [4][8]. - The company’s ESG report emphasizes integrity and compliance, yet the actions taken during the price-fixing period indicate a failure to uphold these standards, raising concerns about the effectiveness of their ethical framework [4][8]. Group 3: Information Disclosure Issues - Xianju Pharmaceutical faced criticism for the delayed disclosure of the penalty information, which was only briefly mentioned in the annual report, leading to investor concerns about transparency and the potential impact on investment decisions [9][10]. - The company disclosed the penalty details on page 182 of the annual report, making it difficult for investors to locate this critical information, which raises questions about the company's commitment to transparent communication [10][12]. Group 4: Investor Reactions - During an earnings call, investors raised numerous questions regarding the penalty and the company's disclosure practices, indicating significant concern over the implications for profitability and stock performance [15]. - The company's responses to investor inquiries about the penalty's impact were deemed insufficient, failing to address concerns about profit, stock price decline, and potential insider information leaks [15].

Core Viewpoint - The National Market Supervision Administration has imposed a total fine of 355 million yuan on four pharmaceutical companies for colluding to raise the price of dexamethasone phosphate raw materials, which saw a price increase of up to 282 times [1] Group 1: Companies Involved - Four companies involved in the price-fixing scheme include Tianjin Pharmaceutical Co., Jiangsu Lianhuan Pharmaceutical Co., Xi'an Guokang Ruijin Pharmaceutical Co., and Zhejiang Xianju Pharmaceutical Co. [1] - The organizer of the collusion, identified as Guo, was fined the maximum amount of 5 million yuan, while four responsible individuals from the companies were fined 600,000 yuan each [1] Group 2: Price Increases - Dexamethasone phosphate raw material prices were raised significantly, with Tianjin Pharmaceutical increasing prices from 9,000 yuan/kg to 13,800 yuan/kg, and Xi'an Guokang Ruijin raising prices from 7,900 yuan/kg to between 10,000 and 38,000 yuan/kg [1] - Zhejiang Xianju Pharmaceutical raised prices from 8,200 yuan/kg to 10,000 yuan/kg, while Jiangsu Lianhuan increased prices from 7,800 yuan/kg to 15,000 yuan/kg [1] Group 3: Market Impact - The collusion led to a severe market supply shortage, with the price of dexamethasone phosphate injection skyrocketing from 0.35 yuan per dose to 98.76 yuan per dose, marking a staggering increase of 282 times [1] - As of March 7, 2024, the monopolistic pricing of dexamethasone phosphate raw materials was still being enforced [1] Group 4: Legal Consequences - The total illegal gains from the price-fixing scheme were calculated as follows: Tianjin Pharmaceutical Co. 42,764,400 yuan, Zhejiang Xianju Pharmaceutical Co. 23,746,680 yuan, Xi'an Guokang Ruijin Pharmaceutical Co. 24,763,156 yuan, and Jiangsu Lianhuan Pharmaceutical Co. 17,899,200 yuan [1] - The fines imposed on the four companies amounted to 355 million yuan, which includes the confiscation of illegal gains and an additional penalty of 8% of the previous year's sales [1]

Core Viewpoint - The article discusses two significant antitrust enforcement cases in the pharmaceutical sector, highlighting the illegal price-fixing activities of four companies regarding the raw material dexamethasone phosphate, which led to substantial fines and penalties [1][2]. Group 1: Antitrust Cases - The first case involves the price-fixing of dexamethasone phosphate raw materials, where four companies collectively raised the price from 8,000 yuan per kilogram to 13,000 yuan, resulting in a total fine and confiscation of 362 million yuan [1]. - The companies involved in the price-fixing scheme include Tianjin Pharmaceutical Co., Zhejiang Xianju Pharmaceutical Co., Jiangsu Lianhuan Pharmaceutical Co., and Xi'an Guokang Ruijin Pharmaceutical Co. [1]. - The investigation revealed that starting from November 2021, an individual named Guo organized meetings and discussions among the companies to agree on price increases, leading to a significant reduction in market competition and increased healthcare costs for consumers [1]. Group 2: Penalties and Enforcement Actions - The Tianjin Market Supervision Administration imposed a maximum fine of 5 million yuan on the individual Guo, while the four companies were fined a total of 354 million yuan based on 8% of their previous year's sales [2]. - Additionally, four responsible individuals from the companies were fined 600,000 yuan each for their roles in the antitrust agreement [2]. - In a related case, a separate antitrust investigation into the injection of neostigmine methylsulfate resulted in fines totaling 223 million yuan, marking the first time personal responsibility for antitrust agreements was pursued against individuals [2].

Group 1 - The State Administration for Market Regulation announced two antitrust enforcement cases in the pharmaceutical sector during a press conference on June 13, 2023 [1] - In the case involving the raw material drug Dexamethasone Sodium Phosphate, four companies collectively raised the price from 8,000 yuan per kilogram to 13,000 yuan, resulting in a total fine of 362 million yuan [1][2] - The companies involved in the price-fixing agreement included Tianjin Jiyuan Pharmaceutical Co., Zhejiang Xianju Pharmaceutical Co., Jiangsu Lianhuan Pharmaceutical Co., and Xi'an Guokang Ruijin Pharmaceutical Co. [1] Group 2 - The Tianjin Market Regulation Commission imposed administrative penalties, including a maximum fine of 5 million yuan on individual Guo, and confiscated illegal gains from the four companies, totaling 354 million yuan [2] - Each of the four companies was fined 8% of their previous year's sales for participating in the price-fixing agreement, and four responsible individuals were fined 600,000 yuan each [2] - In March 2023, authorities also penalized companies involved in a separate case regarding the injection of Neostigmine Methylsulfate, with total fines amounting to 223 million yuan [2]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. was fined approximately 61.04 million yuan for violating the Anti-Monopoly Law during the sale of the raw material dexamethasone phosphate sodium, marking a significant enforcement action under the revised law [1][2][4][5]. Summary by Relevant Sections Administrative Penalties - The total fines from this series of cases exceed 360 million yuan, with Lianhuan Pharmaceutical's fine being a substantial part of this total [7]. - Lianhuan Pharmaceutical was fined 61.04 million yuan, which includes the confiscation of illegal gains of 17.89 million yuan and a fine of approximately 43.14 million yuan based on 8% of its 2023 sales [4][8]. Case Background - The case involved four pharmaceutical companies colluding to raise prices of dexamethasone phosphate sodium, a critical drug for treating severe COVID-19 cases, leading to increased costs for patients and healthcare systems [8][10]. - The collusion lasted for about two and a half years, starting from November 20, 2021, when the agreement was made during a meeting organized by an individual named Guo [8][21]. Enforcement Trends - The case highlights a trend of stricter enforcement of anti-monopoly laws, particularly in the pharmaceutical sector, where raw material monopolies have become a focus for regulatory bodies [10][11]. - The penalties reflect a dual approach of strict punishment for violations and incentives for compliance, as seen in the differentiated penalties based on cooperation with investigations [13][14]. Implications for the Industry - The case serves as a warning for pharmaceutical companies regarding the risks of horizontal agreements and the need for comprehensive compliance systems to prevent anti-competitive behavior [14]. - Companies are encouraged to establish internal reporting mechanisms and crisis response strategies to mitigate risks associated with anti-monopoly violations [14].

Core Viewpoint - The article discusses a recent monopoly case in the raw material drug sector, highlighting the significant penalties imposed on several pharmaceutical companies for price manipulation of dexamethasone phosphate sodium, which has seen a dramatic price increase during the COVID-19 pandemic [3][5][9]. Group 1: Penalties and Financial Impact - Lianhuan Pharmaceutical was fined 61.0382 million yuan, accounting for 72.53% of its projected net profit for 2024 [3][10]. - The total fines for the three involved companies reached 326 million yuan [3]. - The price of dexamethasone surged from 0.35 yuan to 98.76 yuan per unit, a staggering increase of 282 times [5][8]. Group 2: Nature of the Monopoly - The involved companies engaged in a horizontal monopoly agreement, agreeing to stop price competition and raise prices collectively [6][9]. - The actions of these companies are characterized as typical collusion, which is often difficult to detect externally [6][11]. - A key individual organized meetings among the companies to discuss price increases, ensuring the implementation of the monopoly agreement [16][17]. Group 3: Regulatory Environment and Future Implications - The article emphasizes the need for stricter compliance and internal management within pharmaceutical companies to avoid similar incidents in the future [21]. - The penalties serve as a warning to the industry, indicating that both state-owned and private enterprises will face legal consequences for monopolistic behavior [21][22]. - The regulatory framework is evolving, with new guidelines set to enhance oversight in the pharmaceutical sector, including provisions for reverse payment agreements and indirect price fixing [22][23].

Group 1 - The State Financial Supervision Administration and seven other departments issued measures to support financing for small and micro enterprises, emphasizing the establishment of a coordination mechanism for financing support [1] - The measures include conducting extensive visits to small and micro enterprises to assess their operational status and financing needs, facilitating direct access to bank credit [1] - There is a focus on addressing the operational difficulties faced by small and micro enterprises and encouraging support for key sectors such as foreign trade, private enterprises, technology, and consumption [1] Group 2 - In May 2025, a total of 130 domestic online games were approved by the National Press and Publication Administration [2] Group 3 - The State Council announced the removal of Wang Jianjun from the position of Vice Chairman of the China Securities Regulatory Commission [3] Group 4 - The Shanghai Municipal Government issued a plan to boost consumption, which includes measures to promote reasonable income growth and improve wage distribution mechanisms [4] - The plan aims to enhance the minimum wage adjustment mechanism and support the development of the rural economy and new business models [4] Group 5 - Shanghai is accelerating the introduction of childcare subsidies and maternity social security subsidies as part of its efforts to build a family-friendly society [5] - The city plans to explore increasing parental leave and spouse's paternity leave while enhancing the quality of public kindergartens [5] Group 6 - The Ministry of Foreign Affairs stated that China has the capability and confidence to handle external risks, including tariff wars, as evidenced by a 2.4% year-on-year increase in total goods import and export in the first four months of the year [6] - Exports grew by 7.5%, indicating strong international competitiveness despite high tariff barriers [6] Group 7 - The Ministry of Foreign Affairs expressed strong opposition to the EU's unilateral sanctions against Chinese companies, emphasizing the need for fair trade practices [8] - The ministry highlighted that normal business interactions between Chinese and Russian companies should not be disrupted by these sanctions [8] Group 8 - The Dalian Commodity Exchange announced trading arrangements for the Dragon Boat Festival period, with a market closure from May 31 to June 2, 2025, and a return to normal trading on June 3 [9] Group 9 - Heng Rui Pharmaceutical set the issuance price for its H-shares at HKD 44.05 per share [11] - Xinyuan Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [11] - The company Guokai Microelectronics is planning a major asset restructuring, leading to a suspension of its stock from May 22 [11]

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的关于黄体酮软胶囊的《药品注册证书》（证书编号：2025S01275、 2025S01276），公司黄体酮软胶囊被批准注册。现将相关情况公告如下： 申请内容：境内生产药品注册上市许可。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他相关情况 黄体酮软胶囊，规格为0.1g和0.2g，参比制剂为原研进口的黄体酮软胶囊， 商品名：安琪坦®（Utrogestan®）。该参比制剂由比利时Besins Healthcare开发， 0.1g规格于1981年9月在比利时批准上市，0.2g规格于2006年1月在比利时批准上 市。1992年10月，安琪坦®0.1g规格在中国获批进口，2013年5月，安琪坦®0.2g 规格在中国获批进口。黄体酮软胶囊的适应症为用于黄体缺乏引起的机能障碍， 有助于妊娠。Besins Healthcare的黄体酮软胶囊已在荷兰、法国、英国、瑞士、 1 证券代码：002332 证券简称：仙琚制药 公告编号：2025-026 浙江仙琚制 ...